A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. The disease, characterized by constricted airways due to bronchitis and emphysema, is commonly seen in smokers but ...

Infections, not eosinophilic inflammation, are the primary cause of asthma exacerbations in patients receiving benralizumab.

Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic ...

In one phase 3 trial, former smokers with COPD receiving itepekimab had a significantly lower annualized moderate/severe ...

Please provide your email address to receive an email when new articles are posted on . 15.4% of the population had frequent exacerbations. Greater frequency was associated with higher corticosteroid ...

Gavin C. Donaldson, PhD; John R. Hurst, PhD; Christopher J. Smith, BA; Richard B. Hubbard, DM; Jadwiga A. Wedzicha, MD We based our analysis on a health-care definition of exacerbation, with our major ...

Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without ...

Table 1 reports the total number of patients with COPD and the number experiencing an MI or stroke. There were 25,857 patients with COPD in 277 practices at the start of the observation period. Over ...